Common complaints among consumers of cannabis edibles include the presence an unpleasant taste, but this and other inadequacies are being overcome through the innovations of Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP). Lexaria’s disruptive process masks the unpleasant taste of cannabis, and the company’s lipophilic enhancement technology also changes the way cannabinoids enter the body while significantly speeding up the timeframe in which THC’s effects are felt and increasing bio-absorption by as much as tenfold. As noted in a recent NNW article:
“Because cannabinoids are absorbed poorly by the gastrointestinal tract, many cannabis users turn to other administration routes, like smoking, for greater effectiveness. Lexaria’s proprietary technology for better delivery of bioactive compounds solves the problem of poor absorption, increasing the bio-absorption of cannabis edibles by between five and tenfold. The effects of the THC from an edible product created using Lexaria’s patented process are also felt much more quickly—taking effect within 15-20 minutes as opposed to one to two hours. The possibilities enabled by Lexaria’s technology are multifold and exciting. For instance, excessive amounts of sugar have previously had to be included in cannabis edibles to mask the unwanted taste, but because Lexaria’s technology eliminates that undesirable flavor, zero-sugar formats are now possible for cannabinoid edibles.”
To view the full article, visit http://dtn.fm/Ffb9W
About Lexaria
Lexaria Bioscience Corp. has developed and out-licenses its disruptive technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit www.lexariabioscience.com.
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment